Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 4

4(66.7%)

N/A

2(33.3%)

6Total

Phase 4(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06640894Not ApplicableRecruiting

Power2Walk: The Impact of Functional Power Training on Participation and Activity in Children With Cerebral Palsy.

Role: collaborator

NCT05649930Recruiting

Effect of Functional Power Training on Calf Muscle Length and Strength in Children With Spastic Paresis

Role: collaborator

NCT05725577Not ApplicableWithdrawn

Rheum@Home: RA Remote Patient Monitoring

Role: collaborator

NCT03895879Phase 4Recruiting

Use of Tocilizumab Drug Levels to Optimize Treatment in RA

Role: lead

NCT04194827Phase 4Recruiting

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Role: lead

NCT04222920Phase 4Completed

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

Role: lead

NCT04251741Phase 4Unknown

Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment

Role: lead

All 7 trials loaded